Cargando…

Treatment with Tocilizumab in Adult Patients with Moderate to Critical COVID‐19 Pneumonia: A Single‐Center Retrospective Study

OBJECTIVES: This study aimed to assess if tocilizumab (TCZ) timing is associated with improved survival. MATERIAL AND METHODS: Data obtained from adult patients with moderate/severe/critical COVID-19 and treated with TCZ, who were admitted to the Teaching Hospital of Infectious Diseases, Cluj-Napoca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Radulescu, Amanda, Istrate, Alexandru, Muntean, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793111/ https://www.ncbi.nlm.nih.gov/pubmed/35093528 http://dx.doi.org/10.1016/j.ijid.2022.01.048

Ejemplares similares

563. Tocilizumab in the Treatment of Critical COVID-19 Pneumonia
por: Fisher, Matthew, et al.
Publicado: (2020)

Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis
por: Hushaw, Linda L, et al.
Publicado: (2010)

Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients
por: Fisher, Matthew J., et al.
Publicado: (2021)

A comparison of hepatitis E and A in a teaching hospital in Northwestern Romania. Acute hepatitis E – a mild disease?
por: Istrate, Alexandru, et al.
Publicado: (2020)

A single-center experience in use of tocilizumab in COVID-19 pneumonia in India
por: Joshi, Aditya, et al.
Publicado: (2021)

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
por: Cardona-Pascual, Ignacio, et al.
Publicado: (2022)

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
por: Cardona-Pascual, Ignacio, et al.
Publicado: (2022)

Effect of tocilizumab versus standard of care in adults hospitalized with moderate-severe COVID-19 pneumonia
por: Aomar-Millán, Ismael F., et al.
Publicado: (2022)

Tocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case series
por: Mady, Ahmed, et al.
Publicado: (2020)

Treatment Outcomes of Tocilizumab in Critically-Ill COVID-19 Patients, Single-Centre Retrospective Study
por: Hafez, Wael, et al.
Publicado: (2022)

Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study
por: López-Medrano, Francisco, et al.
Publicado: (2021)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

69: COMPARING THE OUTCOMES OF GIVING TOCILIZUMAB THEN HEMOPERFUSION, HEMOPERFUSION THEN TOCILIZUMAB, AND NO INTERVENTION IN CRITICAL SARS-COV-2 PNEUMONIA PATIENTS IN MAKATI MEDICAL CENTER
por: Macatangay, M.V.R., et al.
Publicado: (2022)

Antibody and viral RNA kinetics in SARS-CoV2 infected patients admitted to a Romanian University Hospital of Infectious Diseases
por: Radulescu, Amanda, et al.
Publicado: (2021)

Tocilizumab in Combination with Corticosteroids in COVID-19 Pneumonia: A Single-Centre Retrospective Controlled Study
por: Kardos, Zsófia, et al.
Publicado: (2023)

Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review
por: Roomi, Sohaib, et al.
Publicado: (2020)

Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience
por: Jiménez-Brítez, Gustavo, et al.
Publicado: (2020)

Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience
por: Jiménez-Brítez, Gustavo, et al.
Publicado: (2020)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment
por: Yurttutan, Sadık, et al.
Publicado: (2021)

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

Tocilizumab and Cytokine Release Syndrome in COVID-19 Pneumonia: Experience From a Single Center in Pakistan
por: Hassan, Muhammad, et al.
Publicado: (2021)

Efficacy of Tocilizumab in COVID-19: Single-Center Experience
por: Kaya, Safak, et al.
Publicado: (2021)

Tocilizumab and steroid treatment in patients with COVID-19 pneumonia
por: Mikulska, Malgorzata, et al.
Publicado: (2020)

Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study
por: Huang, Edmund, et al.
Publicado: (2021)

Success rate of Remdesivir, Convalescent Plasma, and Tocilizumab in moderate to severe Covid-19 pneumonia: our experience in a tertiary care center
por: Mohanty, Bijaya, et al.
Publicado: (2021)

Treatment of COVID-19 atypical pneumonia by early Tocilizumab administration in “non-critically-ill” patients on hemodialysis
por: Castellano, Giuseppe, et al.
Publicado: (2020)

Prevalence of Hospital-Acquired Pneumonia Among Patients With Severe to Critical COVID-19 Pneumonia Given Tocilizumab
por: Adre, Lorenzo Abednego B, et al.
Publicado: (2023)

External Validation of Mortality Scores among High-Risk COVID-19 Patients: A Romanian Retrospective Study in the First Pandemic Year
por: Rădulescu, Amanda, et al.
Publicado: (2022)

Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study
por: Russo, Gianluca, et al.
Publicado: (2021)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Changes in Inflammatory Markers after Administration of Tocilizumab in COVID-19: A Single-Center Retrospective Study
por: Olewicz-Gawlik, Anna, et al.
Publicado: (2021)

Single versus multiple doses of Tocilizumab in critically ill patients with coronavirus disease 2019 (COVID-19): A two-center, retrospective cohort study
por: Al Sulaiman, Khalid, et al.
Publicado: (2021)

Effects of Tocilizumab on Adults With COVID-19 Pneumonia: A Meta-Analysis
por: Chen, Chi-Chung, et al.
Publicado: (2022)

Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation
por: Potere, Nicola, et al.
Publicado: (2020)

Outcomes associated with tocilizumab with or without corticosteroid versus dexamethasone for treatment of patients with severe to critical COVID-19 pneumonia
por: AlQahtani, Hajar, et al.
Publicado: (2022)

553. Critically Ill patients Receiving Tocilizumab Compared With Those Not Receiving Tocilizumab for Treatment of COVID-19
por: Leonard, Michael, et al.
Publicado: (2020)

Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia
por: Zhang, Shengyu, et al.
Publicado: (2020)

TOCILIZUMAB USE IN SEVERE COVID-19: A SINGLE CENTER EXPERIENCE
por: Poon, Joseph, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_m5smk666c79cf6d27thqg93efl